High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma

详细信息    查看全文

• 作者：Bo Hyun Kim ; Seong-Jang Kim ; Keunyoung Kim ; Heeyoung Kim…
• 关键词：Metabolic tumor volume ; Total lesion glycolysis ; Papillary thyroid carcinoma ; Lymphatic metastasis
• 刊名：Annals of Nuclear Medicine
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：29
• 期：8
• 页码：721-729
• 全文大小：532 KB
• 参考文献：1.Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2(3):159鈥?1.CrossRef PubMed
  2.Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, Larson SM, Erdi AK, et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med. 2000;27(7):861鈥?.CrossRef PubMed
  3.Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, et al. Prognostic significance of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73(3):332鈥?.CrossRef PubMed
  4.Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53(5):709鈥?5.CrossRef PubMed
  5.Hs I. Kim SJ, Kim IJ, Kim K. Predictive value of metabolic tumor volume measured by 18F-FDG PET for regional lymph node status in patients with esophageal cancer. Clin Nucl Med. 2012;37(5):442鈥?.CrossRef
  6.Romesser PB, Qureshi MM, Shah BA, Chatburn LT, Jalisi S, Devaiah AK, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med. 2012;26(7):527鈥?4.PubMed Central CrossRef PubMed
  7.Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2013;40(2):290鈥?01.CrossRef PubMed
  8.Stack BC Jr, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid. 2012;22(5):501鈥?.CrossRef PubMed
  9.Lee DW, Ji YB, Sung ES, Park JS, Lee YJ, Park DW, et al. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol. 2013;39(2):191鈥?.CrossRef PubMed
  10.Lee YJ, Kim DW, Kyoung Park H, Kim DH, Jung SJ, Oh M, et al. Pre-operative ultrasound diagnosis of nodal metastasis in papillary thyroid carcinoma patients according to nodal compartment. Ultrasound Med Biol. 2015;41(5):1294鈥?00.CrossRef PubMed
  11.Yasuda S, Shohtsu A, Ide M, Takagi S, Takahashi W, Suzuki Y, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology. 1998;207(3):775鈥?.CrossRef PubMed
  12.Kim BH, Kim SJ, Kim H, Jeon YK, Kim SS, Kim IJ, et al. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma. Nucl Med Commun. 2013;34(9):868鈥?6.PubMed
  13.Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract. 2000;6(6):469鈥?6.CrossRef PubMed
  14.Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5(1):3鈥?3.
  15.Kim TY, Kim WG, Kim WB, Shong YK. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul). 2014;29(3):217鈥?5.CrossRef
  16.Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48(2):221鈥?.PubMed
  17.Wang W, Larson SM, Fazzari M. Prognostic value of [18F]-fluorodeoxy glucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab. 2000;85(3):1107鈥?3.PubMed
  18.Jeong HS, Chung M, Baek CH, Ko YH, Choi JY, Son YI. Can [18F]-fluorodeoxyglucose standardized uptake values of PET imaging predict pathologic extrathyroid invasion of thyroid papillary microcarcinomas? Laryngoscope. 2006;116(12):2133鈥?.CrossRef PubMed
  19.Yun M, Noh TW, Cho A, Choi YJ, Hong SW, Park CS, et al. Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab. 2010;95(7):3182鈥?.CrossRef PubMed
  20.Ortiz S, Rodr铆guez JM, Soria T, P茅rez-Flores D, Pi帽ero A, Moreno J, et al. Extrathyroid spread in papillary carcinoma of the thyroid: clinicopathological and prognostic study. Otolaryngol Head Neck Surg. 2001;124(3):261鈥?.CrossRef PubMed
  21.Radowsky JS, Howard RS, Burch HB, Stojadinovic A. Impact of degree of extra-thyroidal extension of disease on papillary thyroid cancer outcome. Thyroid. 2014;24(2):241鈥?.CrossRef PubMed
  22.Arora N, Turbendian HK, Scognamiglio T, Wagner PL, Goldsmith SJ, Zarnegar R, et al. Extrathyroidal extension is not all equal: implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery. 2008;144(6):942鈥?.CrossRef PubMed
  23.Kim JM, Lee YY, Choi CW, Lim SM, Lee S, Cho SY, et al. The clinical importance of minimal extrathyroidal extension on tumor recurrence in patients with papillary thyroid carcinoma. Endocrinol Metab. 2010;25(4):340鈥?.CrossRef
  24.Hatt M, Le Pogam A, Visvikis D, Pradier O. Cheze Le Rest C. Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer. J Nucl Med. 2012;53(1):12鈥?0.PubMed Central CrossRef PubMed
  25.Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932鈥?5.CrossRef PubMed
  26.Geets X, Lee JA, Bol A, Lonneux M, Gr茅goire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging. 2007;34(9):1427鈥?8.CrossRef PubMed
  27.Schaefer A, Kremp S, Hellwig D, R眉be C, Kirsch CM, Nestle U. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008;35(11):1989鈥?9.CrossRef PubMed
  
• 作者单位：Bo Hyun Kim (1)
  Seong-Jang Kim (2)
  Keunyoung Kim (2)
  Heeyoung Kim (2)
  So Jung Kim (2)
  Won Jin Kim (1)
  Yun Kyung Jeon (1)
  Sang Soo Kim (1)
  Yong Ki Kim (3)
  In Joo Kim (1)
  
  1. Department of Internal Medicine, School of Medicine, Pusan National University and Biomedical Research Institute, 179 Gudeok-Ro, Seo-Gu, Busan, 602-739, Korea
  2. Department of Nuclear Medicine, School of Medicine, Pusan National University and Biomedical Research Institute, 179 Gudeok-Ro, Seo-Gu, Busan, 602-739, Korea
  3. Kim Yong Ki Internal Medicine Clinic, Chungmu-dong 1-ga, Seo-gu, Busan, 602-011, Korea
  
• 刊物主题：Nuclear Medicine; Imaging / Radiology;
• 出版者：Springer Japan
• ISSN：1864-6433

文摘

Objective The objective of this study was to investigate whether total lesion glycolysis (TLG) and metabolic tumor volume (MTV) measured by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) could predict the aggressiveness and lymph node metastasis (LNM) in patients with incidentally detected differentiated thyroid carcinoma.